Price Target Update on Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals (NASDAQ:INO) : 5 Wall Street analysts covering Inovio Pharmaceuticals (NASDAQ:INO) believe that the average level the stock could reach for the short term is $18.6. The maximum price target given is $31 and the minimum target for short term is around $13, hence the standard deviation is calculated at $7.23.

Other Equity analysts have also commented on the company shares. Equity Analysts at the Brokerage Firm, Brean Capital, maintains their rating on the shares of Inovio Pharmaceuticals (NASDAQ:INO). Brean Capital has a Buy rating on the shares. As per the latest research report, the brokerage house lowers the price target to $18 per share from a prior target of $20. The rating by the firm was issued on March 14, 2016.

Inovio Pharmaceuticals (NASDAQ:INO): On Thursdays trading session , Opening price of the stock was $10.26 with an intraday high of $10.36. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $9.545. However, the stock managed to close at $9.85, a loss of 3.43% for the day. On the previous day, the stock had closed at $10.2. The total traded volume of the day was 3,238,473 shares.

The company shares have rallied 21.72% from its 1 Year high price. On Apr 28, 2016, the shares registered one year high at $11.69 and the one year low was seen on Jan 20, 2016. The 50-Day Moving Average price is $10.43 and the 200 Day Moving Average price is recorded at $8.08. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Benito Simon X, director of Inovio Pharmaceuticals, Inc., had unloaded 6,250 shares at an average price of $10.37 in a transaction dated on May 18, 2016. The total value of the transaction was worth $64,813.

Inovio Pharmaceuticals, Inc. (Inovio) is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. As of December 31, 2014, Inovio had completed clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), HIV, influenza and Ebola. With its immunotherapy platform consisting of SynCon products, as well as its CELLECTRA electroporation delivery technology, Inovio has developed a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. Inovios immunotherapies are delivered into cells of the body into a small local area of tissue using its electroporation (EP) DNA delivery technology.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.